Therapies that stimulate IFN1 and CXCL10 production,such as toll-like receptor agonists and IFNα are currently under several trialsacross cancers.12 Poly I:C-based pre-clinical and human trials areongoing but have not shown a benefit yet.13 Moreover, clinical trials using IFN alone as atherapeutic approach showed toxic side effects and local accumulation. Here, IFNA1 is linked to cancer.